{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:20:51Z","timestamp":1715883651210},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives de P\u00e9diatrie"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.arcped.2013.12.023","type":"journal-article","created":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T09:30:38Z","timestamp":1391419838000},"page":"314-321","source":"Crossref","is-referenced-by-count":5,"title":["Pourquoi utiliser les macrolides au long cours en pneumologie p\u00e9diatrique\u00a0?"],"prefix":"10.1016","volume":"21","author":[{"given":"H.","family":"Corvol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Taytard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Thouvenin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"P\u00e9risson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcped.2013.12.023_bib0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0021-8707(70)90124-3","article-title":"The use of macrolide antibiotic substances in the treatment of asthma","volume":"45","author":"Itkin","year":"1970","journal-title":"J Allergy"},{"key":"10.1016\/j.arcped.2013.12.023_bib0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/ajrccm\/147.2.398","article-title":"A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids","volume":"147","author":"Nelson","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.arcped.2013.12.023_bib0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0091-6749(80)90003-2","article-title":"Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma","volume":"66","author":"Zeiger","year":"1980","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 9A","key":"10.1016\/j.arcped.2013.12.023_bib0020","first-page":"12S","article-title":"Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases","volume":"117","author":"Kudoh","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0025","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0030","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/thx.50.12.1246","article-title":"Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection","volume":"50","author":"Fujii","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.arcped.2013.12.023_bib0035","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0954-6111(03)00042-8","article-title":"Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis","volume":"97","author":"Kadota","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.qco.0000160901.71813.fe","article-title":"Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections","volume":"18","author":"Parnham","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.arcped.2013.12.023_bib0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.biocel.2011.05.009","article-title":"Macrolides: new therapeutic perspectives in lung diseases","volume":"43","author":"Guillot","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"issue":"Suppl 9A","key":"10.1016\/j.arcped.2013.12.023_bib0050","first-page":"2S","article-title":"Immunomodulatory properties of macrolides: overview and historical perspective","volume":"117","author":"Rubin","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0055","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1378\/chest.125.2_suppl.70S","article-title":"Immunomodulatory activity and effectiveness of macrolides in chronic airway disease","volume":"125","author":"Rubin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.arcped.2013.12.023_bib0060","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.arcped.2013.12.023_bib0065","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.48.5.1581-1585.2004","article-title":"Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kappaB activation","volume":"48","author":"Desaki","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcped.2013.12.023_bib0070","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.arcped.2013.12.023_bib0075","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.arcped.2013.12.023_bib0080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10238-005-0070-7","article-title":"Autoantibodies against bactericidal\/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin","volume":"5","author":"Rotschild","year":"2005","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0085","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2013.12.023_bib0090","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2013.12.023_bib0095","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","article-title":"Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection","volume":"102","author":"Steinkamp","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.arcped.2013.12.023_bib0105","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.200502-218OC","article-title":"Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis","volume":"172","author":"Saiman","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcf.2004.09.001","article-title":"Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study","volume":"4","author":"Hansen","year":"2005","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2013.12.023_bib0115","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1569-1993(03)00021-3","article-title":"Improved lung function and body mass index associated with long-term use of macrolide antibiotics","volume":"2","author":"Pirzada","year":"2003","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arcped.2013.12.023_bib0120","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2013.12.023_bib0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.inf.0000247109.44249.ac","article-title":"Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function","volume":"26","author":"Tramper-Stranders","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.arcped.2013.12.023_bib0275","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2013.12.023_bib0135","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dkr040","article-title":"Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review","volume":"66","author":"Cai","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcped.2013.12.023_bib0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.prrv.2012.08.001","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"13","author":"Southern","year":"2012","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.arcped.2013.12.023_bib0145","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2013.12.023_bib0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00151829-200504020-00005","article-title":"The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis","volume":"4","author":"Cymbala","year":"2005","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0155","first-page":"540","article-title":"Prophylactic antibiotic treatment of bronchiectasis with azithromycin","volume":"59","author":"Davies","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.arcped.2013.12.023_bib0160","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","article-title":"Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations","volume":"105","author":"Serisier","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.arcped.2013.12.023_bib0165","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.arcped.2013.12.023_bib0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.99.13236199","article-title":"A pilot study of low-dose erythromycin in bronchiectasis","volume":"13","author":"Tsang","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arcped.2013.12.023_bib0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arcped.2013.12.023_bib0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2710.2006.00708.x","article-title":"Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis","volume":"31","author":"Yalcin","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.arcped.2013.12.023_bib0185","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1183\/09031936.97.10050994","article-title":"Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study","volume":"10","author":"Koh","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arcped.2013.12.023_bib0190","first-page":"CD002997","article-title":"Macrolides for chronic asthma","author":"Richeldi","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2013.12.023_bib0195","first-page":"CD002997","article-title":"Macrolides for chronic asthma","author":"Richeldi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arcped.2013.12.023_bib0200","first-page":"23","article-title":"Utility of adjunctive macrolide therapy in treatment of children with asthma: a systematic review and meta-analysis","volume":"6","author":"Mikailov","year":"2013","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.arcped.2013.12.023_bib0205","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/all.12199","article-title":"Macrolides for the long-term management of asthma\u00a0\u2013\u00a0a meta-analysis of randomized clinical trials","volume":"68","author":"Reiter","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.arcped.2013.12.023_bib0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2500\/aap.2007.28.2958","article-title":"Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report","volume":"28","author":"Piacentini","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.arcped.2013.12.023_bib0215","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1378\/chest.106.2.458","article-title":"Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma","volume":"106","author":"Shimizu","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.arcped.2013.12.023_bib0220","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0091-6749(93)90345-G","article-title":"Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma","volume":"91","author":"Kamada","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0225","first-page":"264","article-title":"Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children","volume":"139","author":"Eitches","year":"1985","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.arcped.2013.12.023_bib0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ppul.1950100308","article-title":"Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma","volume":"10","author":"Flotte","year":"1991","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0235","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009988","article-title":"Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin","volume":"2013","author":"Thouvenin","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.arcped.2013.12.023_bib0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-2999(96)00552-3","article-title":"Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1\u00a0activity","volume":"314","author":"Van Bambeke","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0245","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1128\/AAC.00663-13","article-title":"Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcped.2013.12.023_bib0250","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ppul.21240","article-title":"Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"45","author":"Jubin","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0255","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcped.2013.12.023_bib0260","doi-asserted-by":"crossref","first-page":"L746","DOI":"10.1152\/ajplung.00292.2012","article-title":"Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion","volume":"304","author":"Tarran","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0265","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bph.12187","article-title":"A novel macrolide\/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition","volume":"169","author":"Kobayashi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.arcped.2013.12.023_bib0270","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/jpet.112.200733","article-title":"A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition","volume":"345","author":"Kobayashi","year":"2013","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Archives de P\u00e9diatrie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X13006611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929693X13006611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T04:15:57Z","timestamp":1565151357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929693X13006611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0929693X13006611"],"URL":"https:\/\/doi.org\/10.1016\/j.arcped.2013.12.023","relation":{},"ISSN":["0929-693X"],"issn-type":[{"value":"0929-693X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}